A Phase 2 interventional study of HMI-115 and Placebo in Endometriosis, sponsored by Hope Medicine (Nanjing) Co., Ltd. Completed at 5 sites in 3 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.
Among the 169 studies in Endometriosis with a site in United States, this one is the 26th largest by enrollment of the 131 interventional ones that give a count, is one of 4 that started in 2021, is one of 39 in phase 2, and was the 113th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
LOAM Science · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Staci Gruber, Ph.D. · Sites in United States
Ages 21+ · Women only
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
169 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 45 · Phase 3 22 · Phase 4 14
First in 1998; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 60 across the 131 interventional studies, 187 across the 38 observational. Of the 102 that completed or were terminated, 50 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 169 have an industry lead sponsor. The 10 most frequent:
Hope Medicine (Nanjing) Co., Ltd is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Hope Medicine (Nanjing) Co., Ltd has 2 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
21 of the studies in Endometriosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
| NCT05245695Aspira Women's HealthDeep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) | 2026-11-30 |
| NCT06477406Mclean HospitalEvaluating the Impact of a Novel Cannabinoid Product for Endometriosis | 2026-12 |
| NCT05059626Penn State UniversityEndometriosis and Microvascular Dysfunction; Simvastatin and Duavee | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 169 studies in Endometriosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
This study aims to evaluate the safety and efficacy of HMI-115 versus a placebo in pre-menopausal women with moderate to severe Endometriosis associated pain.
The study will determine the safety and efficacy of HMI 115 at 3 dose levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once Every 2 weeks, subcutaneously injection
Drug: HMI-115
Once Every 2 weeks, subcutaneously injection
Drug: HMI-115
Once Every 2 weeks, subcutaneously injection
Drug: HMI-115
Once Every 2 weeks, subcutaneously injection
Drug: Placebo
HMI-115 is human monoclonal antibody
Placebo
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change)
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, Week 12
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change)
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, Week 12
Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale(NRS) From Baseline to Week 24 (Percentage Change)
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, Week 24
Change in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Percentage Change)
The Numeric Rating Scale for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, week 12 and 24
Change in Dyspareunia (DYSP) Measured by NRS From Baseline to Week 12 and 24 (Percentage Change)
The Numering Rating Score for dyspareunia ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, week 12 and 24
Change From Baseline (CFB) in the Monthly Mean Endometriosis Daily Impact Pain Scale for DYS, NMPP and DYSP
Endometriosis Daily Impact Pain Scale ranges from 0 (none) to 3 (severe) as recorded in a daily electronic diary. The higher scores mean worse outcome.
Time frame: Baseline, week 12 and 24
Change From Baseline (CFB) by Visit in Permitted Rescue Medication Use
Assessment was based on average pill counts at each apecific period od days
Time frame: Baseline, week 12 and 24
Change in Menstrual Period Heaviness (Bleeding) From Baseline by Visit
Assessment was based on tampons or pads used. 0 means no bleeding, 4 means heavy bleeding. Higher score means more bleeding.
Time frame: Baseline, week 12 and 24
Change in Dysmenorrhea(DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 24 (Absolute Score Change)
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, Week 24
Change in Non-menstrual Pelvic Pain (NMPP) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 and 24 (Absolute Score Change)
The Numeric Rating Scale (NRS) for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, Week12, Week24
Change in Dyspareunia (DYSP) Measured by Numering Rating Score(NRS) From Baseline to Week 12 and 24 (Absolute Score Change)
The Numering Rating Score(NRS) for dyspareunia(DYSP) ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
Time frame: Baseline, Week12, Week24
The study was conducted in China, the United States of America (USA), and Poland.Total of 310 subjects were screened, of which 142 subjects were randomized. Among them, 36 subjects received HMI-115 60 mg, 36 received HMI-115 120 mg, 35 received HMI-115 240 mg, and 35 subjects were randomized to receive placebo. In the protocol version 5.0, part 2 of the study was deleted and not executed. So no subject was recruited in the former planned part 2 study.
| Milestone | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Started | 36 | 36 | 35 | 35 |
| Completed | 36 | 33 | 35 | 34 |
| Not completed | 0 | 3 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 |
| Withdrew: Early withdrawl | 0 | 0 | 0 | 1 |
| Milestone | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Started | 36 | 33 | 35 | 34 |
| Completed | 35 | 30 | 33 | 34 |
| Not completed | 1 | 3 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Patient decide to have oral contraception/refuse to come back | 0 | 2 | 1 | 0 |
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| percentage of change from baseline | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change) | -27.35 ± 9.568 | -34.72 ± 9.630 | -41.57 ± 10.234 | -18.61 ± 8.859 |
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| score on a scale | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12(Absolute Score Change) | -2.57 ± 0.542 | -3.29 ± 0.546 | -3.26 ± 0.579 | -2.31 ± 0.502 |
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| percentage of change from baseline | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale(NRS) From Baseline to Week 24 (Percentage Change) | -6.86 ± 11.912 | -21.82 ± 12.039 | -14.07 ± 12.736 | 3.97 ± 10.898 |
The Numeric Rating Scale for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| percentage of change from baseline | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Week12 %CFB | -33.74 ± 10.283 | -47.48 ± 10.363 | -51.66 ± 11.157 | -27.61 ± 9.577 |
| Week24 %CFB | -11.22 ± 15.063 | -56.62 ± 15.252 | -38.05 ± 16.341 | -33.30 ± 13.800 |
The Numering Rating Score for dyspareunia ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| percentage of change from baseline | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Week12 %CFB | -7.01 ± 19.073 | -38.43 ± 20.420 | -11.70 ± 22.342 | -24.98 ± 16.627 |
| Week24 %CFB | -2.32 ± 28.065 | -61.91 ± 30.048 | 3.47 ± 30.259 | -13.17 ± 22.422 |
Endometriosis Daily Impact Pain Scale ranges from 0 (none) to 3 (severe) as recorded in a daily electronic diary. The higher scores mean worse outcome.
| score on a scale | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Week 12 DYS | -0.83 ± 0.184 | -1.06 ± 0.185 | -1.13 ± 0.197 | -0.79 ± 0.172 |
| Week 24 DYS | -0.60 ± 0.192 | -0.87 ± 0.194 | -0.66 ± 0.205 | -0.48 ± 0.176 |
| Week12 NMPP | -0.49 ± 0.119 | -0.61 ± 0.119 | -0.69 ± 0.128 | -0.46 ± 0.110 |
| Week24 NMPP | -0.42 ± 0.162 | -0.78 ± 0.165 | -0.63 ± 0.178 | -0.49 ± 0.149 |
| Week12 DYSP | -0.01 ± 0.169 | -0.48 ± 0.173 | -0.16 ± 0.187 | -0.02 ± 0.149 |
| Week24 DYSP | -0.19 ± 0.210 | -0.69 ± 0.230 | -0.28 ± 0.222 | -0.13 ± 0.179 |
Assessment was based on average pill counts at each apecific period od days
| pill | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| CFB Week12 Average pill count Tier 1 | -0.656 ± 1.4020 | -0.463 ± 0.9113 | -1.001 ± 1.4900 | -0.384 ± 0.8579 |
| CFB Week24 Average pill count Tier1 | -0.394 ± 1.4724 | -0.643 ± 1.8192 | -0.590 ± 1.1144 | -0.414 ± 0.9968 |
Assessment was based on tampons or pads used. 0 means no bleeding, 4 means heavy bleeding. Higher score means more bleeding.
| score on a scale | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| CFB Week 12 Average Score | -0.415 ± 0.7062 | -0.571 ± 0.6114 | -0.363 ± 0.6437 | -0.197 ± 0.4525 |
| CFB Week 24 Average score | -0.119 ± 0.6463 | -0.390 ± 0.8419 | -0.585 ± 0.6965 | -0.114 ± 0.4920 |
The Numeric Rating Scale for dysmenorrhea ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| score on a scale | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Change in Dysmenorrhea(DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 24 (Absolute Score Change) | -1.87 ± 0.579 | -2.95 ± 0.585 | -2.18 ± 0.617 | -1.45 ± 0.529 |
The Numeric Rating Scale (NRS) for non-menstrual pelvic pain (NMPP) ranges 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| score on a scale | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Week12 | -1.46 ± 0.344 | -1.64 ± 0.347 | -1.92 ± 0.373 | -1.36 ± 0.321 |
| Week24 | -1.21 ± 0.452 | -2.07 ± 0.457 | -1.67 ± 0.490 | -1.26 ± 0.415 |
The Numering Rating Score(NRS) for dyspareunia(DYSP) ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.
| score on a scale | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Week12 | -0.23 ± 0.487 | -1.33 ± 0.489 | -0.90 ± 0.518 | -0.54 ± 0.423 |
| Week 24 | -1.03 ± 0.547 | -2.13 ± 0.591 | -1.57 ± 0.546 | -0.68 ± 0.456 |
Collected over All AEs and SAEs will be collected from the signing of informed consent form until the end of study participation (About 34 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HMI-115 60mg | 0/27 (0%) | 0/27 (0%) | 15/27 (55.6%) |
| HMI-115 120mg | 0/27 (0%) | 0/27 (0%) | 16/27 (59.3%) |
| HMI-115 240mg | 0/24 (0%) | 1/24 (4.2%) | 18/24 (75%) |
| Placebo | 0/30 (0%) | 0/30 (0%) | 11/30 (36.7%) |
| Event | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| Breast massReproductive system and breast disorders | 0/27 | 0/27 | 1/24 | 0/30 |
| Event | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/27 | 1/27 | 4/24 | 0/30 |
| DizzinessNervous system disorders | 1/27 | 1/27 | 1/24 | 4/30 |
| Injection site pruritusGeneral disorders | 1/27 | 2/27 | 3/24 | 1/30 |
| AmenorrhoeaReproductive system and breast disorders | 1/27 | 0/27 | 3/24 | 0/30 |
| Injection site rashGeneral disorders | 2/27 | 3/27 | 1/24 | 0/30 |
| NasopharyngitisInfections and infestations | 1/27 | 3/27 | 2/24 | 1/30 |
| PyrexiaGeneral disorders | 1/27 | 0/27 | 1/24 | 3/30 |
| Ovarian cystReproductive system and breast disorders | 0/27 | 0/27 | 1/24 | 3/30 |
| NauseaGastrointestinal disorders | 1/27 | 1/27 | 2/24 | 3/30 |
| Injection site reactionGeneral disorders | 1/27 | 2/27 | 2/24 | 0/30 |
PAS:All subjects in the FAS(All randomized subjects who take at least one dose of IMP) who have surgical diagnosis.
| Age, Continuous(years) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 39.9 ± 4.43 | 36.4 ± 4.99 | 37.4 ± 5.31 | 38.1 ± 5.17 | 38.0 ± 5.05 |
| Sex: Female, Male(Participants) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 27 | 27 | 24 | 30 | 108 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 2 |
| Not Hispanic or Latino | 26 | 27 | 24 | 29 | 106 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 12 | 13 | 9 | 15 | 49 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 15 | 14 | 14 | 15 | 58 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| United States | 1 | 1 | 1 | 2 | 5 |
| China | 12 | 13 | 9 | 15 | 49 |
| Poland | 14 | 13 | 14 | 13 | 54 |
| Endometriosis duration(months) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 67.2 ± 37.8 | 57.0 ± 31.8 | 67.4 ± 28.7 | 73.7 ± 27.2 | 66.5 ± 31.7 |
| BMI(kg/m2) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 23.57 ± 4.011 | 23.17 ± 3.220 | 24.40 ± 4.046 | 23.25 ± 4.223 | 23.57 ± 3.873 |
| DYS NRS(units on a scale) | HMI-115 60mg | HMI-115 120mg | HMI-115 240mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 6.288 ± 1.4261 | 6.393 ± 2.1123 | 5.910 ± 1.8236 | 5.696 ± 2.0005 | 6.127 ± 1.7909 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Sep 2024, 35 months.
Results were first posted in Nov 2025, 1 year 1 month after primary completion.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 35 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HMI-115
Hope Medicine (Nanjing) Co., Ltd